We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Blood Test for Early Immune Response to SARS-CoV-2 Could Enable Early Detection of Serious COVID-19 Patients

By LabMedica International staff writers
Posted on 08 Dec 2020
A new way of testing whether the immune system of COVID-19 patients is preparing to fight the SARS-CoV-2 virus could be used for early identification of those patients whose immune systems are not responding appropriately and are therefore, at a higher risk of serious infection.

The prototype test developed by researchers at the QIMR Berghofer Medical Research Institute (Brisbane, Australia) detects high levels of two key chemical signals that are produced by T cells when they recognize SARS-CoV-2-infected cells and begin fighting the infection. More...
For their study, the researchers examined blood donated by recovered COVID-19 patients in order to find out which combination of viral peptides can be used to stimulate T cells in the laboratory and allow researchers to measure their response to SARS-CoV-2.

"We isolated the T cells from the donated blood, exposed them to viral peptides, and measured the production of a number of different signaling molecules. We then compared the levels produced by T cells from the recovered COVID-19 patients with levels released by T cells from 20 healthy donors who had never been infected with SARS-CoV-2," said Associate Professor Corey Smith who was the study leader and is the head of QIMR Berghofer's Translational and Human Immunology Group. "We found that T cells from people who had recovered from COVID-19 produced larger amounts of the signaling molecules interferon gamma and interleukin-2, which are involved in killing virus-infected cells and encouraging other T cells to come to the infected area."

"We screened a range of SARS-CoV-2 peptides to work out which combination could be used to detect a successful T cell immune response, which we can then measure by detecting these two key signaling molecules."

The researchers believe that a blood test for early immune response to the virus could help countries that are witnessing second and third COVID-19 waves.

"Now that we've refined a way to detect whether or not T cells are reacting to SARS-CoV-2, we believe this information could be used to develop a blood test," said QIMR Berghofer researcher Dr. Katie Lineburg. "A blood test could help doctors identify patients whose T cells have not started mounting an immune response and who are therefore not fighting the virus and are at higher risk of becoming seriously unwell. Those patients could then be monitored more closely to ensure they receive treatment early, rather than waiting until they experience severe symptoms."

Related Links:
QIMR Berghofer Medical Research Institute


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.